this way we are able to offer scientists the newest and best research tools available globally regardless of source. in addition, we operate a robust framework of systems and controls to maintain high standards throughout the company. one area that has become increasingly attractive to us is broadening abcam’s offerings as a development and supply partner in the diagnostics market. consumers our comprehensive consumer insights, personalised support, data and continually growing range of resources are helping to accelerate scientific discovery. it has been a year of progress for abcam as we have once again delivered on our financial goals. this is a model we are replicating across many commercial agreements around the world to establish future growth for our business. we are resolutely focused on delivering a high quality solution that is scalable and will deliver future efficiency improvements. read more on our kpis page 14 10 abcam plc annual report and accounts 2017 strategic report our markets government investment into research remains flat for the fiscal year starting april 2017. japan’s declining population, meaning fewer researchers, alongside the lack of increased budget for science and technology has meant that japan’s global share of scientific publications is decreasing. abcam is proud to be partnering with in2science and this year launched an image competition for the students during their research placements. there is always room for improvement and we have identified some areas around board process to develop in the coming year. mara’s specific focus areas are in her operational expertise including acquisition integration, global manufacturing, quality systems and strategic marketing. mara aspinall mba non-executive director n r louise patten ma (oxon) non-executive and senior independent director n a r gavin wood ba (hons), aca chief financial officer annual report and accounts 2017 abcam plc corporate governance 31 appointment: december 2014. background: a chemist by training, sue began her career at ford motor co. before moving to oil company amerada hess. jonathan milner phd deputy chairman appointment: april 1998. background: having worked in the life sciences industry for over ten years as an academic researcher, jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded abcam with dr david cleevely and professor tony kouzarides. there has been additional oversight of this important programme at board level with a focus on its broader reach across the group. within this context, i would like to provide you with an overview of the committee’s major decisions during 2016/17. abcam has achieved strong financial growth, while also investing significantly in the people, systems and infrastructure required to support our continued expansion. our performance in the year against these kpis is presented on page 14. the table below shows each strategic kpi measure, its relative weighting and an indication of the targets: strategic measure weighting threshold target exceed maximum rabmab ® primaries cer revenue growth 13% 17%–19% 19%–21% 21%–23% >23% non-primaries cer revenue growth 7% 19%–21% 21%–23% 23%–25% >25% nps 10% 20%–26% 26%–30% 30%–32% >32% market position 3% target to maintain #1 position in research primary antibodies as well #1 or #2 in at least two other areas achievement was as follows: below threshold threshold target exceed maximum % of maximum 0% 25% 50% 75% 100% rabmab ® primaries cer revenue growth  non-primaries cer revenue growth  nps  market position  overall out-turn was 59.1% of the maximum. all abp and ltip targets will be fully disclosed after vesting, unless full disclosure would expose the business to a clear competitive risk. 46 abcam plc annual report and accounts 2017 corporate governance remuneration report continued part 3 – annual report on remuneration continued audited information continued d) executive director departure arrangements chief financial officer (jeff iliffe) jeff iliffe served notice of his intention to step down from the position of chief financial officer on 14 september 2015. the committee considered the overall circumstances of his departure as an executive director, as well as performance, contractual obligations and scheme plan rules. they can, however, sell sufficient shares to satisfy any tax liability that may arise on the release or exercise of an award. 49 annual report and accounts 2017 abcam plc corporate governance audited information continued f) directors’ shareholdings and share interests continued annual bonus plan deferred share awards deferred share awards made under the abp which remain outstanding at 30 june 2017 are outlined below: executive directors nil-cost options or conditional shares held as at 30 june 2016 1 nil-cost options or conditional shares awarded during the year ended 30 june 2017 2 award date market price per share at award planned vesting date maximum nil-cost options or conditional shares held as at 30 june 2017 alan hirzel 27,475 9,169 26 oct 16 816.6 pence 26 oct 18 26,106 jeff iliffe 3 31,258 — 31,258 jim warwick 3 39,123 1,899 41,022 gavin wood — — — 97,856 11,068 98,386 1 these relate to the awards made in september 2013, november 2014 and october 2015 under the abp for financial years 2012/13, 2013/14 and 2014/15, respectively. for further details, please refer to the pension-related and other benefits section on page 45. non-executive directors during 2015/16 the company put in place fee arrangements for all neds where a portion of their fees would be delivered as a fixed number of fully paid ordinary shares. no person has any special rights of control over the company’s share capital and all issued shares are fully paid. • we performed specified procedures over certain account balances and transaction classes at other group companies, including another chinese operation. the relevant calculations are also performed manually, necessitating a substantive approach to testing that appropriate amounts of labour and overhead cost have been capitalised. for inventory manufactured in house and hybridomas, we agreed, on a sample basis, the quality test results to underlying records. 72 abcam plc annual report and accounts 2017 financial statements notes to the financial statements continued for the year ended 30 june 2017 3. significant accounting policies continued retirement benefit costs payments to defined contribution retirement benefit schemes are charged as an expense as they fall due. the group tests whether goodwill is impaired on at least an annual basis or more frequently when there are indications of possible impairment. the group recognises liabilities for anticipated tax audit issues based on estimates of whether additional taxes will be due. it was concluded that these attributes were available for utilisation and would be utilised within the required time limits. the fair value is remeasured on a monthly basis with reference to available forward market rates and comparative instrument pricing. any other changes in the book values of each loan are attributable to foreign exchange movements, and intergroup settlements. for example, biological pathways can trigger the assembly of new molecules, turn genes on and off, or spur a cell to move. investor relations 330 cambridge science park milton road cambridge cb4 0fl uk email: corporate@abcam.com phone: +44 (0)1223 696000 website: www.abcamplc.com financial calendar financial year end 30 june 2017 full year results announced 11 september 2017 annual general meeting 14 november 2017 ex-dividend date for final dividend 16 november 2017 record date for final dividend 17 november 2017 final dividend payment 8 december 2017 108 abcam plc annual report and accounts 2017 corporate directory the abcam group’s commitment to environmental issues is reflected in the production of this annual report which has been printed on cocoon 100, an fsc ® certified and pcf (process chlorine free) paper made from 100% post-consumer waste paper fibres.